Status:
COMPLETED
A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Multiple myeloma is a rare form of malignancy in which neoplastic plasma cells accumulate in the bone marrow. Most malignant plasma cells continue to produce immunoglobulin. The activity of multiple m...
Eligibility Criteria
Inclusion
- Patients 18 years of age with a definite diagnosis of multiple myeloma.
- Patients have been on a steady dose of INTRON®A for at least 6 weeks and have tolerated it (randomized study only), or patients who within six weeks of starting INTRON®A become intolerant (tolerability sub-study only)
- Informed consent obtained
Exclusion
- \- a) Patients with refractory Multiple Myeloma. b) Treatment with any investigational drug within 30 days of entry to this protocol.
- c) Subjects who are pregnant, nursing, or of reproductive potential and who are not practising an effective means of contraception.
Key Trial Info
Start Date :
March 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00323505
Start Date
March 1 2001
End Date
December 1 2004
Last Update
May 9 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden NHS trust
Sutton, Surrey, United Kingdom, SM2 5PT